Johnson & Johnson COVID-19 vaccine

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Retrieved on: 
Wednesday, May 11, 2022

ENA Respiratory is the first Australian company to be selected to join Blue Knight.

Key Points: 
  • ENA Respiratory is the first Australian company to be selected to join Blue Knight.
  • Blue Knight offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases.
  • As a Blue Knight company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.
  • ENA Respiratorys self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses.

Where Americans Stand on Coronavirus and Mask Mandates on Planes: Long Island University Hornstein Center National Poll

Retrieved on: 
Monday, April 25, 2022

Americans were asked if they supported the removal of mask mandates onboard airline flights to reduce the likelihood of contracting the coronavirus; 42% of respondents said yes.

Key Points: 
  • Americans were asked if they supported the removal of mask mandates onboard airline flights to reduce the likelihood of contracting the coronavirus; 42% of respondents said yes.
  • Overall, 53% of respondents said yes, the highest since June 2021 through national polls conducted by the Long Island University Steven S. Hornstein Center for Policy, Polling and Analysis.
  • This Long Island University Steven S. Hornstein Center for Policy, Polling, and Analysis online poll was conducted through SurveyMonkey from April 21 22, 2022 among a national sample of 1,584 adults ages 18 and up.
  • ABOUT THE LONG ISLAND UNIVERSITY STEVEN S. HORNSTEIN CENTER FOR POLICY, POLLING, AND ANALYSIS
    The Long Island University Steven S. Hornstein Center for Policy, Polling, and Analysis conducts independent polling, empirical research, and analysis on a wide range of public issues.

Second COVID-19 Boosters Now Available at All Rite Aid Locations for Eligible Individuals

Retrieved on: 
Wednesday, March 30, 2022

PHILADELPHIA, March 30, 2022 /PRNewswire/ -- Rite Aid (NYSE: RAD) today announced it will begin administering a second booster of the mRNA Pfizer and Moderna COVID-19 vaccines for eligible individuals, following approval by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).

Key Points: 
  • Individuals aged 50 and older and certain immunocompromised individualsaged 12 and older may receive a second booster at least four months after their first booster.
  • Eligible adults who received a primary vaccine and booster dose of Johnson & Johnson's Janssen COVID-19 vaccine at least four months ago may also receive a second booster dose using an mRNA vaccine.
  • Customers may receive their second booster dose at Rite Aid regardless of where they received their primary series or first booster.
  • "To date, Rite Aid has administered over 15 million COVID-19 vaccinations and encourages anyone who hasn't received their primary vaccination series to do so, and to get their booster shots when eligible."

IBM Employees' Questions About the COVID-19 Vaccine Mandate Continue to Go Unanswered

Retrieved on: 
Tuesday, February 8, 2022

IBM also stated that it will allow those who work from home to continue to do so, at least temporarily.

Key Points: 
  • IBM also stated that it will allow those who work from home to continue to do so, at least temporarily.
  • As IBM continues its COVID-19 vaccine mandate, US IBM employees opposed to the mandate still have unanswered questions.
  • Since then, a reply was received, but their questions continue to go unanswered.
  • Concerned IBMers are hoping that IBM will see this as an opportunity to lead the industry and drop its own mandate.

Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients

Retrieved on: 
Wednesday, February 2, 2022

The guidance recommends that all rheumatic disease patients receive a booster dose after their primary vaccine series, as recommended by the CDC.

Key Points: 
  • The guidance recommends that all rheumatic disease patients receive a booster dose after their primary vaccine series, as recommended by the CDC.
  • These recommendations for primary vaccination, supplemental dosing, and booster doses apply regardless of whether patients have experienced natural COVID-19 infection.
  • It remains important for rheumatology providers to assess the vaccination status of all patients with rheumatic diseases, said Dr. Jeffrey Curtis, Chair of the ACR COVID-19 Vaccine Guidance Task Force.
  • Rheumatologists are experts in the diagnosis, management, and treatment of more than 100 different types of arthritis and rheumatic diseases.

Global Pharmaceutical Packaging Industry 2021 - Temperature-sensitive Packaging for New-generation Biologics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 14, 2022

The "Global Pharmaceutical Packaging Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pharmaceutical Packaging Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has not only revealed supply chain challenges in terms of meeting pandemic-induced demand but also showcased weaknesses with regard to facing disruptions on a global scale.
  • Therefore, local manufacturing deals, supply chain investments, and packaging innovation will continue to play important roles in the global push for immunization.
  • For the biopharma industry, positive long-term developments and growth opportunities can outweigh the detrimental short-term impacts of the ongoing pandemic.

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

Retrieved on: 
Wednesday, December 15, 2021

NEW BRUNSWICK, N.J., Dec. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a 'mix and match' booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting).

Key Points: 
  • "We are pleased with today's Positive Opinion from the CHMP supporting the use of our COVID-19 vaccine as a booster for eligible individuals in Europe," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • The CHMP recommendation is supported by latest data for heterologous boosting with the Johnson & Johnson COVID-19 vaccine.
  • A single booster dose of the Janssen COVID-19 Vaccine may be administered at least two months after primary vaccination with the Janssen COVID-19 Vaccine.
  • You should seek medical attention right away if you have any of the following symptoms after receiving the Janssen COVID-19 Vaccine:

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

Retrieved on: 
Wednesday, December 15, 2021

NEW BRUNSWICK, N.J., Dec. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a 'mix and match' booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting).

Key Points: 
  • "We are pleased with today's Positive Opinion from the CHMP supporting the use of our COVID-19 vaccine as a booster for eligible individuals in Europe," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • The CHMP recommendation is supported by latest data for heterologous boosting with the Johnson & Johnson COVID-19 vaccine.
  • A single booster dose of the Janssen COVID-19 Vaccine may be administered at least two months after primary vaccination with the Janssen COVID-19 Vaccine.
  • You should seek medical attention right away if you have any of the following symptoms after receiving the Janssen COVID-19 Vaccine:

Where Americans Stand on the Coronavirus and Vaccine Mandates: Long Island University Hornstein Center National Poll

Retrieved on: 
Wednesday, November 17, 2021

WHERE AMERICANS STAND ON CORONAVIRUS MANDATES:

Key Points: 
  • WHERE AMERICANS STAND ON CORONAVIRUS MANDATES:
    Americans were asked if they supported coronavirus vaccine mandates healthcare workers, first responders, teachers, airline pilots, all employees, and students age 12 and older.
  • WHERE AMERICANS STAND ON CORONAVIRUS VACCINE FOR YOUTH:
    Americans were asked if they would recommend adolescents from age 12 to 17 get vaccinated with an FDA authorized COVID vaccine.
  • ABOUT THE LONG ISLAND UNIVERSITY STEVEN S. HORNSTEIN CENTER FOR POLICY, POLLING, AND ANALYSIS
    The Long Island University Steven S. Hornstein Center for Policy, Polling, and Analysis conducts independent polling, empirical research, and analysis on a wide range of public issues.
  • Long Island University, founded in 1926, continues to redefine higher education, providing high quality academic instruction by world-class faculty.

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Retrieved on: 
Friday, October 15, 2021

Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.

Key Points: 
  • Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.
  • "Johnson & Johnson is steadfast in its commitment to protect as many people globally as possible against the continued spread of COVID-19," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • You should not get the Janssen COVID-19 Vaccine if you:
    had a severe allergic reaction to any ingredient of this vaccine.
  • You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine: